Biotechnology

Biogen

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

Biogen announces Alzheimer's drug fails to meet primary endpoint in mid-stage trial

Leqembi® Iqlik™ PDUFA date updated to August 24th

FDA Prioritizes Review of LEQEMBI® IQLIK™ Subcutaneous Injection for Early Alzheimer's Disease

Canaccord Genuity Analyst Maintains Buy Rating for Biogen

Biogen Reports Strong Q1 Earnings and Seeks to Acquire Apellis

Biogen released FY2026 Q1 earnings on April 29 Pre-Market (EST), actual revenue USD 2.478 B (forecast USD 2.248 B), actual EPS USD 2.15 (forecast USD 2.1916)

Biogen Reports Q1 Earnings Beat and Adjusts Lower Full-Year Guidance

Biogen Reports Q4 2024 Earnings: Yearly Revenue Down 2%, Forecasting Moderate Decline in 2025

Biogen to Release FY2026 Q1 Earnings on April 29 Pre-Market EST, Forecast Revenue USD 2.25 B, EPS USD 2.2166

Biogen Obtains Exclusive Rights to CD38 Antibody Felzartamab

Citi and Truist Cut Biogen's Target Price

Biogen plans to acquire Apellis

Biogen expects 2026 Q1 EPS at 0.19 USD with R&D expenses of 34 million USD

Biogen Gets FDA Approval for New High-Dose Spinraza for Spinal Muscular Atrophy

Canaccord Genuity Group Raises Biogen's Target Price to $245

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

NextNRG

InMed Pharmaceuticals

Amesite

Meiwu Tech

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

CN Energy

MetaVia

Generation Income Properties

Co-Diagnostics

BIIB

SBIO

IBBQ

LABU

ARKG

Goldman Sachs analyst Salveen Richter has reiterated a Buy rating on Biogen, raising the price target from $238 to $250. This decision is driven by the strong performance of Leqembi, which exceeded revenue expectations in the recent quarter. Factors supporting this outlook include a favorable revenue forecast from Eisai, anticipated catalysts for broader use of biomarkers, and potential new formulations that could enhance treatment options.

- Goldman Sachs analyst Salveen Richter maintains a buy rating on Biogen and raises the target price to $250.00, reflecting confidence in Leqembi's strong performance.  
- Leqembi's recent earnings exceeded expectations and showed robust sales in the U.S., Japan, and China, reinforcing optimism in Alzheimer's treatment growth.  
- Factors supporting this positive outlook include Eisai's revenue forecast for Leqembi, potential approval of new treatments, and enhanced opportunities outside the U.S.

Tip Ranks

Proshares Ultra Nasdaq Biotech

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VG Health

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Ark Genomic Revolution ETF

iShares Biotechnology ETF

SPDR S&P Biotech

iShares Global Healthcare

Goldman Sachs

Eisai Co., Ltd.

GS Hldg R

Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250

Oppenheimer has raised its price target for Biogen (NASDAQ:BIIB) from $275 to $300, maintaining an 'outperform' rating. This suggests a potential upside of 55.47% from the previous close. Other analysts have also adjusted their targets, with a consensus rating of 'Moderate Buy' and an average target of $215.62. Biogen's stock recently traded at $192.97, with a market cap of $28.49 billion and a P/E ratio of 20.67.

Market Beat

Oppenheimer

Wells Fargo

Morgan Stanley

Citigroup

HSBC

HSBC HOLDINGS

Barclays

Apellis Pharma

First Horizon

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

HSBC 5xShortSG241213

HSBC Holdings Plc

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Oppenheimer Analyst Says

Evercore has initiated coverage on Biogen (NASDAQ:BIIB), assigning an 'outperform' rating. Other analysts have also raised their price targets, with Mizuho increasing it to $236.00. Biogen's stock rose 1.1% to $193.41, with a market cap of $28.56 billion. The company reported strong quarterly earnings, exceeding estimates, and has set FY 2026 guidance at 14.250-15.250 EPS. Institutional investors hold 87.93% of the stock.

Evercore

Mizuho Financial

Mizuho Financial Group, Inc.

Stifel Financial

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Biogen (NASDAQ:BIIB) Now Covered by Evercore

Biogen's shares surged 10% after the company announced progress with its Alzheimer's drug diranersen, despite a mid-stage study not meeting its primary goal. The drug targets tau, a protein linked to Alzheimer's, and showed potential benefits in slowing disease progression. Biogen's head of development highlighted a promising combination of tau reduction and cognitive benefits. This development may reignite interest in tau-targeting treatments, contrasting with current therapies focused on amyloid. Biogen's stock has risen 16% this year, reflecting investor optimism following setbacks in other tau-focused studies.

GuruFocus

Eli Lilly

Johnson & Johnson

Biogen Shares Jump 10% After Advancing Alzheimer's Tau Drug

APLS

Biogen is expanding its focus on immunology, particularly in lupus and kidney disease, as part of its growth strategy. Adam Meyers highlighted the company's late-stage programs, including litifilimab for lupus, which shows promising Phase 2 results. The acquisition of Apellis is expected to enhance Biogen's nephrology capabilities. Meyers emphasized the need for diversification guided by scientific rationale and patient needs, with a focus on leveraging existing expertise from its multiple sclerosis business.

Biogen(BIIB.US)

Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250

Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Oppenheimer Analyst Says

Biogen (NASDAQ:BIIB) Now Covered by Evercore

Biogen Shares Jump 10% After Advancing Alzheimer's Tau Drug

Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push